Mupirocin detailed information
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 97% |
| Elimination half-life | 20 to 40 minutes |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H44O9 |
| Molar mass | 500.622 g/mol |
Mupirocin (Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens NCIMB 10586[1]. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations.[2] It is used topically and effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus[3]. Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90% of the mixture. Also present in mupirocin are pseudomonic acid B with an additional hydroxyl group at C8[4], pseudomonic acid C with a double bond between C10 and C11, instead of the epoxide of PA-A[5], and pseudomonic acid D with a double bond at C4` and C5` in the 9-hydroxy-nonanoic acid portion of mupirocin[6].
Figure 1. The structure of pseudomonic acid A-D, labeled A-D, respectively.
Mechanism
Mupirocin has been shown to strongly inhibit protein and RNA synthesis in Staphylococcus aureus while DNA and cell wall formation were also negatively impacted a lesser degree[7]. The inhibition of RNA synthesis was shown to be a protective mechanism in response to a lack of one amino acid, isoleucine[8]. In vivo studies in Escherichia coli demonstrated that pseudomonic acid inhibits isoleucine t-RNA synthetase (IleRS)[3]. This mechanism of action is shared with furanomycin, an analog of isoleucine[9]
Uses
Mupirocin is used as a topical treatment for bacterial skin infections, for example, furuncle, impetigo, open wounds etc. It is also useful in the treatment of methicillin-resistant Staphyolococcus aureus (MRSA), which is a significant cause of death in hospitalized patients who have received systemic antibiotic therapy. It is suggested, however, that mupirocin not be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.
Resistance
Shortly after the clinical use of Mupirocin began, strains of Staphylococcus aureus that were resistant to mupirocin emerged[10]. Two distinct populations of mupirocin-resistant S. aureus were isolated. One strain possessed low-level resistance, MuL, (MIC = 8-256 mg/L) and another possessed high-level resistance, MuH, (MIC > 256 mg/L)[10]. Resistance in the MuL strains is probably due to mutations in the organism’s wild-type isoleucinyl-tRNA synthetase. In E. coli IleRS, a single amino acid mutation was shown to alter mupirocin resistance[11]. MuH is linked to the acquisition of a separate Ile synthetase gene, mupA[12]. Mupirocin is not a viable antibiotic against MuH strains. Other antibiotic agents such as azelaic acid, nitrofurazone, silver sulfadiazine, and ramoplanin have been shown to be effective against MuH strains[10].
The mechanism of mupirocin differs from other clinical antibiotics rendering cross-resistance to other antibiotics unlikely[10]. However, the MupA gene may co-transfer with other antibacterial resistance genes. This has been observed already with resistance genes for triclosan, tetracycline, and trimethoprim[10].
Biosynthesis
Biosynthesis of Pseudomonic Acid A
The 74 kb mupirocin gene cluster contains six multi-domain enzymes and twenty six other peptides (Table 1)[13]. Four large multi-domain type I polyketide synthase (PKS) proteins are encoded, as well as several single function enzymes with sequence similarity to type II PKSs[13]. It is therefore believed that mupirocin is constructed by a mixed type I and type II PKS system. The mupirocin cluster exhibits an atypical acyltransferase (AT) organization, in that there are only two AT domains and both are found on the same protein, MmpC. These AT domains are the only domains present on MmpC, while the other three type I PKS proteins contain no AT domains[13]. The mupirocin pathway also contains several tandem acyl carrier protein doublets or triplets. This may be an adaptation to increase the throughput rate or to bind multiple substrates simultaneously[13].
Pseudomonic acid A is the product of an esterification between the 17C polyketide monic acid and the 9C fatty acid 9-hydroxy-nonanoic acid. The possibility that the entire molecule is assembled as a single polyketide with a Baeyer-Villiger oxidation inserting an oxygen into the carbon backbone has been ruled out because C1 of monic acid and C9’ of 9-hydroxy-nonanoic acid are both derived from C1 of acetate[14].
Monic acid biosynthesis
Biosynthesis of the 17C monic acid unit begins on MmpD (Figure 2)[13]. One of the AT domains from MmpC may transfer an activated acetyl group from acetyl-Coenzyme A (CoA) to the first ACP domain. The chain is extended by malonyl-CoA, followed by a SAM-dependent methylation at C12 (see Figure 1 for PA-A numbering) and reduction of the B-keto group to an alcohol. The dehydration (DH) domain in module 1 is predicted to be non-functional due to a mutation in the conserved active site region. Module 2 adds another two carbons by malonyl-CoA extender unit, followed by ketoreduction (KR) and dehydration. Module three adds a malonyl-CoA extender unit, followed by SAM-dependent methylation at C8, ketoreduction, and dehydration. Module 4 extends the molecule with a malonyl-CoA unit followed by ketoreduction.
Assembly of monic acid is continued by the transfer of the 12C product of MmpD to MmpA [13]. Two more rounds of extension with malonyl-CoA units are achieved by module 5 and 6. Module 5 also contains a KR domain.
Figure 2. The domain structure of MmpA, MmpC, and MmpD for the synthesis of monic acid. The biosynthesis of monic acid is not colinear but has been rearranged in this diagram. The protein name is displayed inside of the arrow with module and domain structure listed below. ACP=acyl carrier protein, AT=acyl transferase, DH=dehydratase, ER=enoyl reductase, HMG=3-hydroxy-3-methylglutaric acid, MeT=methyl transferase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase. File:Monic acid4.png
Post-PKS tailoring
The keto group at C3 is replaced with a methyl group in a multi-step reaction (Figure 3). MupG begins by decarboxylating a malonyl-ACP. The alpha carbon of the resulting acetyl-ACP is linked to C3 of the polyketide chain by MupH. This intermediate is dehydrated and decarboxylated by MupJ and MupK, respectively[13].
Figure 3. The C15 methyl group of monic acid is attached to C3 by the following reaction scheme. MupH is an 3-hydroxy-3-methylglutarate-Coenzyme A synthase, MupJ and MupK are Enoyl-CoA hydratases[13].
File:Mupirocin C15 methylation.png
The formation of the pyran ring requires many enzyme mediated steps (Figure 4). The double bond between C8 and C9 is proposed to migrate to between C8 and C16[15]. Gene knockout experiments of mupO, mupU, mupV, and macpE have eliminated PA-A production[15]. PA-B production is not removed by these knockouts, demonstrating that PA-B is not created by hydroxylating PA-A. A knockout of mupW eliminated the pyran ring, identifying MupW as being involved in ring formation[15]. It is not known if this occurs before or after the esterification of monic acid to 9-hydroxy-nonanoic acid.
Figure 4. The pyran ring of mupirocin is generated in this proposed multistep reaction [15]. Gene knockouts of mupO, mupU, mupV and macpE abolish PA-A production but not PA-B production, demonstrating that PA-B is a precusor to PA-A[15].
The epoxide of PA-A at C10-11 is believed to be inserted after pyran formation by a cytochrome P450 such as MupO[13]. A gene knockout of mupO abolished PA-A production but PA-B, which also conatins the C10-C11 epoxide, remained[15]. This indicates that MupO is either not involved or is not essential for this epoxidation step.
9-Hydroxy-nonanoic acid biosynthesis
The nine carbon fatty acid 9-hydroxy-nonanoic acid (9-HN) is derived as a separate compound and later esterified to monic acid to form pseudomonic acid. 13C labeled acetate feeding has shown that C1-C6 are constructed with acetate in the canonical fashion of fatty acid synthesis. C7’ shows only C1 labeling of acetate while C8’ and C9’ show a reversed pattern of 13C labeled acetate[14]. It is speculated that C7-C9 arises from a 3-hydroxypropionate starter unit, which is extended three times with malonyl-CoA and fully reduced to yield 9-HN. It has also been suggested that 9-HN is initiated by 3-hydroxy-3-methylglutaric acid (HMG). This latter theory was not supported by feeding of [3-14C] or [3,6-13C2]-HMG[6].
MmpB is proposed to catalyze the synthesis of 9-HN (Figure 5). MmpB contains a KS, KR, DH, 3 ACPs, and a thioesterase (TE) domain[13]. It does not contain an enoyl reductase (ER) domain which would be required for the complete reduction to the nine carbon fatty acid. MupE is a single domain protein that shows sequence similarity to known ER domains and may complete the reaction[13]. It also remains possible that 9-hydroxy-nonanoic acid is derived partially or entirely from outside of the mupirocin cluster.
Figure 5. MmpB is proposed to synthesize 9-HN with a 3-hydroxy-propionate starter unit and three malonyl-CoA extenter units. The domain structure of MmpB is shown below along side with MupE, the proposed enoyl reductase required for complete saturation of 9-HN. ACP=acyl carrier protein, DH=dehydratase, ER=enoyl reductase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase.
Sources
The original manufacturer's (GlaxoSmithKline) product is Bactroban. It is now available as a generic. One source is manufactured by Ortho-McNeil Pharmaceutical called Centany. Another is from Teva Pharmaceutical Industries which is simply called Mupirocin Ointment.[16]
References
- ↑ Fuller AT, Mellows G, Woolford M, Banks GT, Barrow KD, Chain EB (1971). "Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens". Nature. 234 (5329): 416–7. PMID 5003547. Unknown parameter
|month=ignored (help) - ↑ Moodabe, Kate. "Topical antibiotics - more harm than good?". Focus. p. 1. Retrieved 2007-04-20. Unknown parameter
|coauthors=ignored (help) - ↑ 3.0 3.1 Hughes J, Mellows G (1978). "Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid". Biochem. J. 176 (1): 305–18. PMID 365175. Unknown parameter
|month=ignored (help) - ↑ Chain EB, Mellows G (1977). "Pseudomonic acid. Part 3. Structure of pseudomonic acid B". J. Chem. Soc. Perkin Trans. I (3): 318–24. PMID 402373.
- ↑ "ScienceDirect - Tetrahedron Letters : The structure and configuration of pseudomonic acid C". doi:10.1016/S0040-4039(00)71533-4. Missing or empty
|url=(help) - ↑ 6.0 6.1 "The chemistry of pseudomonic acid. Part 6. Structure and preparation of pseudomonic acid D".
- ↑ Hughes J, Mellows G (1978). "On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus". J. Antibiot. 31 (4): 330–5. PMID 659331. Unknown parameter
|month=ignored (help) - ↑ Haseltine WA, Block R (1973). "Synthesis of guanosine tetra- and pentaphosphate requires the presence of a codon-specific, uncharged transfer ribonucleic acid in the acceptor site of ribosomes". Proc. Natl. Acad. Sci. U.S.A. 70 (5): 1564–8. PMID 4576025. Unknown parameter
|month=ignored (help) - ↑ Tanaka K, Tamaki M, Watanabe S (1969). "Effect of furanomycin on the synthesis of isoleucyl-tRNA". Biochim. Biophys. Acta. 195 (1): 244–5. PMID 4982424. Unknown parameter
|month=ignored (help) - ↑ 10.0 10.1 10.2 10.3 10.4 Cookson BD (1998). "The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice". J. Antimicrob. Chemother. 41 (1): 11–8. PMID 9511032. Unknown parameter
|month=ignored (help) - ↑ Yanagisawa T, Lee JT, Wu HC, Kawakami M (1994). "Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase". J. Biol. Chem. 269 (39): 24304–9. PMID 7929087. Unknown parameter
|month=ignored (help) - ↑ Gilbart J, Perry CR, Slocombe B (1993). "High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases". Antimicrob. Agents Chemother. 37 (1): 32–8. PMID 8431015. Unknown parameter
|month=ignored (help) - ↑ 13.00 13.01 13.02 13.03 13.04 13.05 13.06 13.07 13.08 13.09 13.10 El-Sayed AK, Hothersall J, Cooper SM, Stephens E, Simpson TJ, Thomas CM (2003). "Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586". Chem. Biol. 10 (5): 419–30. PMID 12770824. Unknown parameter
|month=ignored (help) - ↑ 14.0 14.1 Feline TC, Jones RB, Mellows G, Phillips L (1977). "Pseudomonic acid. Part 2. Biosynthesis of pseudomonic acid A". J. Chem. Soc. Perkin Trans. I (3): 309–18. PMID 402372.
- ↑ 15.0 15.1 15.2 15.3 15.4 Cooper SM, Laosripaiboon W, Rahman AS; et al. (2005). "Shift to Pseudomonic acid B production in P. fluorescens NCIMB10586 by mutation of mupirocin tailoring genes mupO, mupU, mupV, and macpE". Chem. Biol. 12 (7): 825–33. doi:10.1016/j.chembiol.2005.05.015. PMID 16039529. Unknown parameter
|month=ignored (help) - ↑ Teva Announces Approval Of Mupirocin Ointment
- Pages with script errors
- Pages with reference errors
- Pages with citations using unsupported parameters
- CS1 maint: Multiple names: authors list
- Pages using web citations with no URL
- CS1 maint: Explicit use of et al.
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pages with broken file links
- Antibiotics
- Dermatological preparations
- Epoxides